IDEXX Laboratories (NASDAQ:IDXX) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s What Happened

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $574.96 and traded as high as $576.17. IDEXX Laboratories shares last traded at $575.98, with a volume of 477,765 shares changing hands.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. UBS Group lowered their price objective on IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating on the stock in a research report on Tuesday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Barclays cut their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Eight investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $721.67.

IDEXX Laboratories Stock Performance

The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market cap of $43.42 billion, a PE ratio of 38.76 and a beta of 1.55. The firm has a fifty day moving average price of $534.27 and a 200 day moving average price of $574.09.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the prior year, the company posted $3.50 EPS. The company’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.79% of the company’s stock.

Institutional Trading of IDEXX Laboratories

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new position in IDEXX Laboratories during the 2nd quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Dimensional Fund Advisors LP raised its holdings in IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after purchasing an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its position in IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.